**Specifications Table**TableSubject area*Neuroscience*More specific subject area*Psychiatric disorders*Type of data*Tables*How data was acquired*Affymetrix GeneChip RNA microarray*Data format*Filtered, analysed*Experimental factors*Mouse brain treated with rTMS for 30 days*Experimental features*RNA isolation, global gene expression analyses*Data source location*Wako, Saitama, Japan*Data accessibility*Data are contained within this article*

**Value of the Data**•A global gene expression analysis of mouse cerebrum treated with rTMS for 30 days.•These data may be useful for comparison with microarray data obtained from rTMS of different durations.•Genes identified as differentially expressed in this data set could be useful in further studies on the effects of rTMS on mouse brain.

1. Data {#s0005}
=======

Affymetrix GeneChip microarray analyses of mRNA isolated from mouse cerebrum after 30 days of rTMS revealed altered expression of several genes ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"}, [Table 8](#t0040){ref-type="table"}, [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}), including glutamatergic genes (e.g., glutamate transporter), dopaminergic genes, cholinergic genes, genes of adrenergic signaling in cardiomyocytes and so on.Table 1Gene expression matrix after 30 days rTMS on cerebrum.Table 1**TC IDGSL1CL2CL3CL4C\*\#Description**93320_atCpt1a0.44I0.15I0.3I0.17I40carnitine palmitoyltransferase 1a, liver93372_atAnp32a1.75I2.28I1.59I1.91I40acidic (leucine-rich) nuclear phosphoprotein 32 family, member A95466_atCotl12.41I1.11I2.03I0.83I40coactosin-like 1 (Dictyostelium)103012_atCcl21a0.27I3.54I-1.5D1.6I31chemokine (C-C motif) ligand 21A (serine); chemokine (C-C motif)ligand 21B (leucine); chemokine (C-C motif) ligand 21C (leucine);predicted gene 10591; predicted gene 13304; predicted gene 1987;predicted gene, 21541; C-C motif chemokine 21c                          100307_atNfix1.12I0.62I0.41I-0.05NC30nuclear factor I/X101883_s\_atXlr3a0.03NC1.16I0.74I1.79I30X-linked lymphocyte-regulated 3A; X-linked lymphocyte-regulated3B; X-linked lymphocyte-regulated 3C                          101921_atRab4a0.46I0.27I-0.01NC0.07I30RAB4A, member RAS oncogene family104175_atDlg41.09I1.46I0.41I1.15NC30discs, large homolog 4 (Drosophila)93253_atMapk1-0.04NC0.34I0.34I0.71I30mitogen-activated protein kinase 193924_f\_atTuba3b0.4I0.15I0.11I-0.09NC30tubulin, alpha 3B96295_atPsat10.09NC0.11I0.28I0.44I30phosphoserine aminotransferase 196590_f\_atOtud7b0.59NC0.7I0.33I0.32I30OTU domain containing 7B99598_g\_atGnai20.33I0.67I-0.1NC0.2MI30guanine nucleotide binding protein (G protein), alpha inhibiting 2102009_atCyfip20.53I0.21I-0.33NC-0.6D21cytoplasmic FMR1 interacting protein 2103275_atAtp6v0a10.52I-1.05D1.2I-0.31NC21ATPase, H+ transporting, lysosomal V0 subunit A1104486_atA2m0.27I-0.91D0.83I-0.91NC21alpha-2-macroglobulin104564_atScg30.47I0.32I-0.49D-0.52NC21secretogranin III104643_atWwc10.72I0.47I-0.34NC-0.69D21WW, C2 and coiled-coil domain containing 1160189_atNudt4-0.2NC-0.84D0.63I0.4I21nudix (nucleoside diphosphate linked moiety X)-type motif 4162138_s\_atCbx60.21I0.27I-0.54D-0.71NC21chromobox 693660_atCamk2a1.53I-0.93D2.09I-0.27NC21calcium/calmodulin-dependent protein kinase II alpha95301_atS100a50.6I0.96I-0.86D-0.45NC21S100 calcium binding protein A595785_s\_atRab7-0.36NC-0.91D0.91I0.4I21RAB7, member RAS oncogene family96583_s\_atKif5a-0.13NC-1.32D1.6I0.36I21kinesin family member 5A97458_atGnb10.61I0.8I-0.58D-0.62NC21guanine nucleotide binding protein (G protein), beta 197560_atPsap-0.28NC-1.49D1.74I0.37I21prosaposin98457_atSlc4a40.72I0.35I-0.62NC-0.92D21solute carrier family 4 (anion exchanger), member 499458_i\_atMark20.28I0.46I-0.66D-0.5NC21MAP/microtubule affinity regulating kinase 299481_atAtp1a20.86I0.45I-0.49NC-0.82D21ATPase, Na+/K+ transporting, alpha 2 polypeptide99882_atIds-0.75NC-1.24D0.55I-0.19MI21iduronate 2-sulfatase100012_atLaptm50.63I0.07NC0.34MI-0.35NC20lysosomal-associated protein transmembrane 5100068_atAldh1a10.21I0.16I-0.42NC-0.31NC20aldehyde dehydrogenase family 1, subfamily A1100133_atFyn0.35I0.55I-0.22NC0.06NC20Fyn proto-oncogene100154_atTapbp0.8I0.21I0.28NC-0.19NC20TAP binding protein100380_atGm102570.06NC0.26I-0.21NC0.02I20predicted gene 10257; predicted gene 12657; H3 histone, family 3A;H3 histone, family 3B; H3 histone, family 3C; histone H3.3-like;uncharacterized LOC105242736100494_atFgf10.48NC-0.23NC0.71I0.29I20fibroblast growth factor 1100573_f\_atGpi10.35I0.41I-0.13NC-0.05NC20glucose phosphate isomerase 1100727_atRpl280.36I0.6I-0.26NC-0.02NC20ribosomal protein L28100762_atSema6a2.15I-0.09NC0.39MI-1.7NC20sema domain, transmembrane domain (TM), and cytoplasmicdomain, (semaphorin) 6A[^2]Table 2Gene expression matrix after 30 days rTMS on cerebrum.Table 2**TC IDGSL1CL2CL3CL4C\*^​^\#Description**100774_atSynj2bp0.34I-0.15I-0.28NC-0.08NC20synaptojanin 2 binding protein100892_atNdufaf10.4NC0.31I0.26NC0.29I20NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assemblyfactor 1100992_atPhc10.43I0.24I-0.07NC-0.28NC20polyhomeotic-like 1 (Drosophila)101113_atRhoa0.31I0.16MI0.18NC-0.26NC20ras homolog gene family, member A101419_atTubb4a0.35I0.51I-0.27NC-0.01NC20tubulin, beta 4 A class IVA101441_i\_atItpr20.32I0.25MI-0.18NC-0.57NC20inositol 1,4,5-triphosphate receptor 2101467_atS100b0.06NC0.04NC0.53I0.44I20S100 protein, beta polypeptide, neural101510_atPsme10.21NC0.27I0.08NC0.19I20proteasome (prosome, macropain) activator subunit 1 (PA28 alpha)101578_f\_atActb0.92I0.99I-0.4NC-0.47NC20actin, beta101587_atEphx10.9I0.99I-1.13NC-1.27NC20epoxide hydrolase 1, microsomal101855_atMap60.3I0.15I-0.01NC-0.35NC20microtubule-associated protein 6101923_atPla2g70.47I0.42I-0.08NC-0.18NC20phospholipase A2, group VII (platelet-activating factoracetylhydrolase, plasma)101930_atNfix0.63I0.34MI-0.11NC-0.34NC20nuclear factor I/X101960_atRtcb0.24NC0.3I-0.18NC0.04I20RNA 2\',3\'-cyclic phosphate and 5\'-OH ligase102007_atHccs0.02NC-0.35NC0.41I0.48I20holocytochrome c synthetase102033_atTesk10.42I0.4I0.09NC-0.05NC20testis specific protein kinase 1102063_atPdpk10.87I0.2I-0.2NC-0.46NC203-phosphoinositide dependent protein kinase 1102095_f\_atSpock20.32I0.18MI-0.53NC-0.73NC20sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2102252_atPfdn20.42I0.24I-0.03NC-0.14NC20prefoldin 2102271_atZmiz20.58I0.54I-0.32NC-0.52NC20zinc finger, MIZ-type containing 2102374_atRcan30.27NC-0.03NC0.29I0.12I20regulator of calcineurin 3102384_atSmarca20.42I0.59I-0.31NC-0.04NC20SWI/SNF related, matrix associated, actin dependent regulator ofchromatin, subfamily a, member 2102639_atChst20.47I0.4I-0.04NC-0.21NC20carbohydrate sulfotransferase 2102691_atZfp385a0.88I0.67I-0.18NC-0.56NC20zinc finger protein 385A102700_atTbr10.43I0.41I-0.37NC-0.43NC20T-box brain gene 1102752_atCyfip10.43I0.31I-0.17NC-0.32NC20cytoplasmic FMR1 interacting protein 1102787_atAdgrg10.79I0.26I0.52NC-0.42NC20adhesion G protein-coupled receptor G1102815_atAnxa110.28I0.5I-0.86NC-0.55NC20annexin A11; predicted gene 2260; predicted gene 2274102856_atSox100.39I0.45I-0.08NC-0.14NC20SRY (sex determining region Y)-box 10102912_atTnks20.28I0.34I-0.4NC-0.2NC20tankyrase, TRF1-interacting ankyrin-related ADP-ribosepolymerase 2102942_atSpecc10.3I0.28I-0.35NC-0.43NC20sperm antigen with calponin homology and coiled-coil domains 1103001_atVegfb0.46MI0.15I-0.13NC-0.02NC20vascular endothelial growth factor B103029_atPdcd40.76I0.61I-0.17NC-0.02NC20programmed cell death 4103040_atCd830.02NC0.43I-0.12NC0.11I20CD83 antigen103054_atPolr2a0.43I0.07NC0.23I-0.06NC20polymerase (RNA) II (DNA directed) polypeptide A103090_atUqcc1-0.41NC-0.09NC0.21I0.33I20ubiquinol-cytochrome c reductase complex assembly factor 1103299_atPld40.88I0.03NC1.18I0.36NC20phospholipase D family, member 4103300_atAbcb70.64I-0.12NC0.41I-0.48NC20ATP-binding cassette, sub-family B (MDR/TAP), member 7103305_atItgb40.83I2.63I0.51NC2.83NC20integrin beta 4103369_atKlf130.77I0.36I-0.36NC-0.43NC20Kruppel-like factor 13103370_atLin7c0.35I0.27I0NC-0.21NC20lin-7 homolog C (C. elegans)103404_atRere0.6I0.19I0.05NC-0.15NC20arginine glutamic acid dipeptide (RE) repeats103411_atGna110.23NC0.48I0.1NC0.13I20guanine nucleotide binding protein, alpha 11103584_atCmip0.32I0.46I-0.37NC-0.37NC20c-Maf inducing protein[^3]Table 3Gene expression matrix after 30 days rTMS on cerebrum.Table 3**TC IDGSL1CL2CL3CL4C\*\#Description**103611_atCd470.55I0.59I-0.22NC-0.18NC20CD47 antigen (Rh-related antigen, integrin-associated signaltransducer)103613_atAldoart21.82I1.52I1.42NC1.55NC20aldolase 1 A, retrogene 2103624_atUrm10.25NC-0.2NC0.54I0.36I20ubiquitin related modifier 1 homolog (S. cerevisiae)103663_atPomgnt10.35I0.32I-0.16NC0.07NC20protein O-linked mannose beta 1,2-N-acetylglucosaminyltransferase103682_atUri1-0.04NC0.65I-0.23NC0.27I20URI1, prefoldin-like chaperone103748_atCmip0.78I0.34I-0.03NC-0.27NC20c-Maf inducing protein103771_atRnf2080.48I0.17I-0.16NC-0.32NC20ring finger protein 208104032_atMast30.6I0.36I-0.39NC-0.51NC20microtubule associated serine/threonine kinase 3104034_atAI4641310.63I0.66I-0.77NC-0.4NC20expressed sequence AI464131104214_atSlc7a80.63I0.33I0.09NC0.16NC20solute carrier family 7 (cationic amino acid transporter,y+ system).member 8104244_atMark20.95I0.63I-0.35NC-0.5NC20MAP/microtubule affinity regulating kinase 2104250_atLrrc8a0.53I0.12I-0.36NC-0.64NC20leucine rich repeat containing 8A104316_atGna130.64I0.59I-0.02NC-0.01NC20guanine nucleotide binding protein, alpha 13104352_atBrd40.2MI0.41I-0.37NC-0.33NC20bromodomain containing 4104368_atMapre30.23MI0.56I-0.22NC-0.09NC20microtubule-associated protein, RP/EB family, member 3104380_atSlc35a1-0.23NC0.34I0.02NC0.7I20solute carrier family 35 (CMP-sialic acid transporter), member 1104409_atGrik50.49I0.37I-0.16NC-0.25NC20glutamate receptor, ionotropic, kainate 5 (gamma 2)104415_atFoxp10.47I0.2I-0.12NC-0.18NC20forkhead box P1104514_atEpn10.3I0.11I-0.17NC-0.39NC20epsin 1104546_g\_atCsnk2a11.1I-0.1NC0.97I0.13NC20casein kinase 2, alpha 1 polypeptide; predicted pseudogene 10031104634_atLims10.49NC0.73I-0.16NC0.5I20LIM and senescent cell antigen-like domains 1104650_atAche0.48I0.38I0.19NC-0.12NC20acetylcholinesterase104725_atRhoq0.81I0.61I0.37NC0.02NC20ras homolog gene family, member Q104739_atTcta0.18NC-0.34NC0.66I0.31I20T cell leukemia translocation altered gene104741_atZdhhc90.8I0.14I0.75NC-0.1NC20zinc finger, DHHC domain containing 9104747_atSlc1a10.42I0.44I-0.28NC-0.35NC20solute carrier family 1 (neuronal/epithelial high affinity glutamatetransporter, system Xag), member 1160111_atEif1ax-0.38NC-0.47NC0.48I0.31I20eukaryotic translation initiation factor 1A, X-linked160181_atSyp0.37I0.45I-0.43NC-0.42NC20synaptophysin160184_atErgic10.75I0.12NC0.75I-0.22NC20endoplasmic reticulum-golgi intermediate compartment (ERGIC) 1160190_atSyt40.5I0.68I-0.09NC-0.01NC20synaptotagmin IV160196_atSmap10.37I0.42I-0.59NC-0.48NC20small ArfGAP 1160272_atCbx30.55I0.55I-0.41NC-0.13NC20chromobox 3160414_atSlc38a100.42I-0.17NC0.28I-0.26NC20solute carrier family 38, member 10160417_atKif5b0.34I0.7I-0.23NC0.08NC20kinesin family member 5B160502_atCreg1-0.03NC-0.22NC0.52MI0.14I20cellular repressor of E1A-stimulated genes 1160614_atPten0.6I0.39I-0.13NC-0.36NC20phosphatase and tensin homolog160667_atEvl0.58I0.56I-0.2NC-0.34NC20Ena-vasodilator stimulated phosphoprotein160743_atPole30.41I-0.13NC0.15I-0.44NC20polymerase (DNA directed), epsilon 3 (p17 subunit)160754_atPygm0.66I0.83I-0.34NC-0.1NC20muscle glycogen phosphorylase160942_atCbx60.63I0.23I-0.06NC-0.36NC20chromobox 6161015_atClvs10.11NC0.7I-0.06NC0.71I20clavesin 1161054_atSpock10.62I0.44I-0.13NC-0.05NC20sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1161057_atActr100.35I0.33I-0.36NC-0.41NC20ARP10 actin-related protein 10[^4]Table 4Gene expression matrix after 30 days rTMS on cerebrum.Table 4**TC IDGSL1CL2CL3CL4C\*^​^\#Description**161070_atSpred20.28I0.38I-0.74NC-0.5NC20sprouty-related, EVH1 domain containing 2161167_r\_atUck12.05I-0.84NC2.47I-0.66NC20uridine-cytidine kinase 1161371_r\_atPtprk1.29NC1.29NC3.1I2.98I20protein tyrosine phosphatase, receptor type, K161819_f\_atLaptm50.73I0.48I-0.11NC-0.05NC20lysosomal-associated protein transmembrane 5162134_r\_at2010111I01Rik0.47I-0.14NC0.47I-0.47NC20RIKEN cDNA 2010111I01 gene162182_f\_atKcnab20.54I0.17I-0.22NC-0.73NC20potassium voltage-gated channel, shaker-related subfamily,beta member 2162332_f\_atMapre30.9I1.08I0.08NC-0.03NC20microtubule-associated protein, RP/EB family, member 3162499_f\_atUbe2d2a0.48I0.38I-0.17NC-0.17NC20ubiquitin-conjugating enzyme E2D 2A92180_atH1fx0.42I0.37I-0.38NC-0.51NC20H1 histone family, member X92196_f\_atSf3a20.37I0.29I-0.16NC-0.27NC20splicing factor 3a, subunit 292202_g\_atZbtb160.72I0.66I-0.61NC-0.73NC20zinc finger and BTB domain containing 1692227_s\_atCtnna20.08NC0.36I-0.25NC-0.01I20catenin (cadherin associated protein), alpha 292241_atNfic0.68I0.88I-0.58NC-0.43NC20nuclear factor I/C92247_atArhgap50.6I-0.02NC0.31MI-0.43NC20Rho GTPase activating protein 592350_atMapre10.82I0.42I0.09NC-0.44NC20microtubule-associated protein, RP/EB family, member 192379_f\_atPtprz10.27MI0.49I-0.55NC-0.2NC20protein tyrosine phosphatase, receptor type Z, polypeptide 192397_atAgap10.52I0.2I0.06NC-0.46NC20ArfGAP with GTPase domain, ankyrin repeat and PH domain 192411_atHs1bp30.44I0.12I0.3NC-0.02NC20HCLS1 binding protein 392426_atTspan50.33I0NC0.33I-0.14NC20tetraspanin 592484_atHivep20.5I-0.2NC0.36I-0.45NC20human immunodeficiency virus type I enhancer binding protein 292525_i\_atNacc20.33I0.82I-0.03NC0.4NC20nucleus accumbens associated 2, BEN and BTB (POZ) domaincontaining92528_atAdgrb10.37I0.17I-0.43NC-0.55NC20adhesion G protein-coupled receptor B192586_atGlud10.36NC0.39I-0.13NC0.24I20glutamate dehydrogenase 192621_atPcbp20.43I0.09I-0.08NC-0.49NC20poly(rC) binding protein 292659_atRapgef4-0.28NC-0.73NC0.98I0.66I20Rap guanine nucleotide exchange factor (GEF) 492678_atDdx250.22NC-0.07NC0.17I0.12I20DEAD (Asp-Glu-Ala-Asp) box polypeptide 2592795_atMap40.56I0.5I-0.07NC-0.28NC20microtubule-associated protein 492817_atImp3-0.22NC-0.46NC0.23I-0.03MI20IMP3, U3 small nucleolar ribonucleoprotein, homolog (yeast)92820_atUsp20.64I0.54I-0.28NC-0.34NC20ubiquitin specific peptidase 292821_atUsp20.42I0.29I-0.25NC-0.27NC20ubiquitin specific peptidase 292838_atFscn10.73I0.2NC0.35I-0.16NC20fascin homolog 1, actin bundling protein (Strongylocentrotuspurpuratus)92871_atSel1l0.79I0.4I-0.19NC-0.36NC20sel-1 suppressor of lin-12-like (C. elegans)92927_atEtv10.66I0.27NC0.49I0.26NC20ets variant 192949_atPacsin10.31I0.33I-0.23NC-0.29NC20protein kinase C and casein kinase substrate in neurons 192958_atFoxo30.43I0.11I-0.44NC-0.54NC20forkhead box O393006_atNfic0.33I0.35MI-0.39NC-0.58NC20nuclear factor I/C93047_atNup500.48I-0.61NC0.81I-0.38NC20nucleoporin 5093055_atAnkrd46-0.16NC-0.14NC0.28I0.28I20ankyrin repeat domain 4693058_atEif1a0.02NC0.35I-0.04NC0.26I20eukaryotic translation initiation factor 1A93069_atUbe2d2a0.04NC0.41I-0.04NC0.2I20ubiquitin-conjugating enzyme E2D 2A93129_atCux20.51I0.43I0NC-0.28NC20cut-like homeobox 293147_f\_atCelf40.43I0.23I-0.2NC-0.39NC20CUGBP, Elav-like family member 493246_atNaa150.22I0.55I-0.27NC-0.35NC20N(alpha)-acetyltransferase 15, NatA auxiliary subunit93284_atCirbp-0.27NC0.42I-0.02NC0.54I20cold inducible RNA binding protein93288_atArpc20.23MI0.44I-0.31NC-0.01NC20actin related protein 2/3 complex, subunit 2[^5]Table 5Gene expression matrix after 30 days rTMS on cerebrum.Table 5**TC IDGSL1CL2CL3CL4C^\*^​^^\#Description**93374_atJph30.44I0.38I-0.25NC-0.17NC20junctophilin 393382_atPde1b0.61I0.29I0.04NC-0.27NC20phosphodiesterase 1B, Ca2+-calmodulin dependent93423_atLdoc1l0.51I0.31I0.21NC-0.14NC20leucine zipper, down-regulated in cancer 1-like93548_atSec. 61b-0.12NC-0.3NC0.29I0.11I20Sec. 61 beta subunit93645_atRgs7-0.02NC0.53I-0.03NC0.45I20regulator of G protein signaling 793659_atCamk2a1.66I-0.95NC1.5I-0.55NC20calcium/calmodulin-dependent protein kinase II alpha93664_atAtp1b20.78I-0.28NC0.76I-0.15NC20ATPase, Na+/K+ transporting, beta 2 polypeptide93720_atAgpat10.27MI-0.71NC0.51I-0.23NC201-acylglycerol-3-phosphate O-acyltransferase 1(lysophosphatidic acid acyltransferase, alpha)93793_atLasp10.43I0.28I-0.14NC-0.24NC20LIM and SH3 protein 193852_atMef2a0.2I0.25I-0.04NC-0.12NC20myocyte enhancer factor 2A93861_f\_atLOC1052473280.29I-0.33NC0.56I-0.05NC20MLV-related proviral Env polyprotein-like93964_s\_atDdx60.81I0.36I0.14NC-0.46NC20DEAD (Asp-Glu-Ala-Asp) box polypeptide 693965_r\_atDdx60.88I0.59I0.23NC-0.17NC20DEAD (Asp-Glu-Ala-Asp) box polypeptide 693994_atChpt10.4I0.27I0.15NC0.16NC20choline phosphotransferase 194057_g\_atScd10.32I0.43I-0.12NC-0.03NC20stearoyl-Coenzyme A desaturase 194077_f\_atRpn20.49MI0.29I-0.13NC-0.27NC20ribophorin II94194_s\_atHcn20.84I0.33I-0.23NC-0.61NC20hyperpolarization-activated, cyclic nucleotide-gated K+ 294218_atTcp10.27I0.49I-0.05NC0.35NC20t-complex protein 194245_atVimp0.08NC0.26I0.04NC0.09I20VCP-interacting membrane protein94257_atRraga0.08NC-0.07NC0.47I0.17I20Ras-related GTP binding A94335_r\_atIna0.45I0.14I-0.25NC-0.63NC20internexin neuronal intermediate filament protein, alpha94336_atOtub10.76I0.43I0NC-0.55NC20OTU domain, ubiquitin aldehyde binding 194353_atEif4ebp21.04MI-0.37NC0.4I-0.98NC20eukaryotic translation initiation factor 4E binding protein 294374_atWdr130.13NC0.03MI0.06NC0.09MI20WD repeat domain 1394456_atSet-0.13NC0.77I-0.14NC0.79I20SET nuclear oncogene94819_f\_atCcni0.3I0.28I-0.4NC-0.28NC20cyclin I94832_atHnrnph20.45NC0.95I0.21NC0.83I20heterogeneous nuclear ribonucleoprotein H294876_f\_atGorasp20.29I0.27I-0.35NC-0.5NC20golgi reassembly stacking protein 294986_atGng30.34I0.27I-0.13NC-0.17NC20guanine nucleotide binding protein (G protein), gamma 395010_atTraf30.29I-0.08NC0.31I-0.02NC20TNF receptor-associated factor 395159_atGm135520.1NC0.35I-0.15NC0.22I20predicted gene 13552; mitochondrial ribosomal protein S18B95397_atD430019H16Rik0.45I0.28I0.04NC-0.3NC20RIKEN cDNA D430019H16 gene95432_f\_atTomm70a0.01NC0.35I-0.32NC0.13MI20translocase of outer mitochondrial membrane70 homolog A (yeast)95447_atMdp1-0.4NC-0.23NC0.43MI0.41I20magnesium-dependent phosphatase 195468_atEgln10.4I0.11NC0.26I0.1NC20egl-9 family hypoxia-inducible factor 195530_atGtf2a10.13NC-0.1NC0.29I0.13I20general transcription factor II A, 195721_atMapkapk20.36I-0.21NC0.6I-0.02NC20MAP kinase-activated protein kinase 295883_atJade10.25MI0.54I-0.54NC-0.14NC20jade family PHD finger 195927_f\_at0.55MI0.65I-0.2NC-0.14NC2096007_atSsr3-0.12NC-0.3NC0.24I0.16I20signal sequence receptor, gamma96056_atRhoc0.57I-0.23NC0.46I-0.12NC20ras homolog gene family, member C96065_atLxn0.55I0.73I-0.43NC0.12NC20latexin96088_atNdrg20.44I0.48I-0.28NC-0.34NC20N-myc downstream regulated gene 296102_i\_atRad23b-0.07NC0.26I-0.26NC0.12I20RAD23b homolog (S. cerevisiae)96186_atLrp100.58I-0.1NC0.42I-0.28NC20low-density lipoprotein receptor-related protein 10[^6]Table 6Gene expression matrix after 30 days rTMS on cerebrum.Table 6**TC IDGSL1CL2CL3CL4C\*^​^\#Description**96191_atArfgef10.59I0.17I0.24NC-0.28NC20ADP-ribosylation factor guanine nucleotide-exchange factor 1(brefeldin A-inhibited)96211_atDpp80.38I-0.08NC0.23MI-0.23NC20dipeptidylpeptidase 896255_atBnip3l-0.01NC0.37I-0.09NC0.15I20BCL2/adenovirus E1B interacting protein 3-like96313_atRasgrf10.71I0.76I-0.25NC-0.19NC20RAS protein-specific guanine nucleotide-releasing factor 196360_atArhgdia0.33I0.13I-0.02NC-0.17NC20Rho GDP dissociation inhibitor (GDI) alpha96518_atWwc10.33I0.31I-0.34NC-0.5NC20WW, C2 and coiled-coil domain containing 196593_atElk10.74I-0.53NC1.15I0.06NC20ELK1, member of ETS oncogene family96674_atTnpo3-0.17NC0.57I-0.38NC0.14I20transportin 396725_atCic0.81I0.27I0.12NC-0.54NC20capicua homolog (Drosophila)96731_atDdx60.39I0.38I-0.09NC-0.34NC20DEAD (Asp-Glu-Ala-Asp) box polypeptide 696741_atPhf120.46I0.48I-0.46NC-0.17NC20PHD finger protein 1296784_atAnln-0.27NC-0.1NC0.7I0.32I20anillin, actin binding protein96811_atRab31-0.01NC0.01NC0.16I0.04I20RAB31, member RAS oncogene family96813_f\_atOtud50.35I0.53I-0.33NC-0.1NC20OTU domain containing 596884_atCarhsp1-0.1NC0.06NC0.49I0.51I20calcium regulated heat stable protein 196920_atHtra10.68I0.29I-0.24NC-0.62NC20HtrA serine peptidase 196955_atAtp6v0e20.04NC0.03NC0.17I-0.01I20ATPase, H+ transporting, lysosomal V0 subunit E297210_at1700037H04Rik0.76I-0.13NC0.32I-0.16NC20RIKEN cDNA 1700037H04 gene97243_atSlc9a3r10.51I0.39I-0.18NC-0.36NC20solute carrier family 9 (sodium/hydrogen exchanger), member 3regulator 197365_atCoro2b0.46I0.26I-0.17NC-0.36NC20coronin, actin binding protein, 2B97450_s\_atAldh7a10.46I-0.07NC0.42I-0.22NC20aldehyde dehydrogenase family 7, member A197487_atSerpine20.32NC0.29I0.05NC0.1I20serine (or cysteine) peptidase inhibitor, clade E, member 297530_atUbe2i0.01NC0.18NC0.33I0.36I20ubiquitin-conjugating enzyme E2I97536_atWdtc10.68I0.03I-0.03NC-0.49NC20WD and tetratricopeptide repeats 197740_atDusp160.46NC0.53I0.46NC0.69MI20dual specificity phosphatase 1697770_s\_atFam3c0.53I0.63I-0.43NC-0.49NC20family with sequence similarity 3, member C97776_atDrd20.75I1.11I0.1NC0.27NC20dopamine receptor D297794_atSema7a2.38I-0.83NC4.45I0.15NC20sema domain, immunoglobulin domain (Ig), and GPI membraneanchor, (semaphorin) 7A97841_atChmp2a0.05NC0.37I-0.18NC0.28I20charged multivesicular body protein 2A97974_atZfpm10.72I0.2I0.12NC-0.54NC20zinc finger protein, multitype 197998_atAtn10.7I0.44I0.19NC-0.03NC20atrophin 198004_atPkia0.11NC-0.53NC1.12I0.31I20protein kinase inhibitor, alpha98011_atGabbr10.24I0.3I-0.21NC-0.23NC20gamma-aminobutyric acid (GABA) B receptor, 198026_g\_atEvi2a-0.31NC-0.24NC0.28I0.6I20ecotropic viral integration site 2a98073_atCux10.46I0.27I0.24NC-0.05NC20cut-like homeobox 198114_atNpc10.49I0.38I-0.11NC-0.24NC20Niemann-Pick type C198127_atCapza20.09NC0.5I-0.11NC0.22I20capping protein (actin filament) muscle Z-line, alpha 298129_atTmsb100.35I0.25MI-0.41NC-0.72NC20thymosin, beta 1098141_atEif5b0.34I0.43I-0.58NC-0.29NC20eukaryotic translation initiation factor 5B98150_atRab11b0.27I0.19I-0.23NC-0.31NC20RAB11B, member RAS oncogene family98169_s\_atFzd30.39I-0.49NC0.46I-0.41NC20frizzled homolog 3 (Drosophila)98454_atPalm0.4I0.14MI0NC-0.25NC20paralemmin98477_s\_atAnk30.57I0.29I-0.29NC-0.51NC20ankyrin 3, epithelial[^7]Table 7Gene expression matrix after 30 days rTMS on cerebrum.Table 7**TC IDGSL1CL2CL3CL4C\*\#Description**98543_atCtss-0.18NC0.3I-0.03NC0.25I20cathepsin S98550_atSet-0.1NC0.46I-0.25NC0.09I20SET nuclear oncogene98564_f\_atGm66540.39I0.47I-0.29NC-0.2NC20predicted pseudogene 6654; 40S ribosomal protein S26-like;ribosomal protein S2698588_atFah-0.15NC-0.21NC0.21I0.58I20fumarylacetoacetate hydrolase98590_atSdc40.69I0.12I-0.42NC-0.76NC20syndecan 498602_atRangap10.5I0.27I0.09NC-0.01NC20RAN GTPase activating protein 198616_f\_atMyh70.64I0.16I-0.43NC-1.01NC20myosin, heavy polypeptide 7, cardiac muscle, beta98827_i\_atKif5a0.24NC-1.04NC1.74I0.33I20kinesin family member 5 A98866_atDlx60.92I1.99I0.7NC2.14NC20distal-less homeobox 698925_atVamp20.91I0.33NC0.76I0.19NC20vesicle-associated membrane protein 298993_atPpp2r5c0.23MI0.35I0.08NC0.02NC20protein phosphatase 2, regulatory subunit B\', gamma99023_atPafah1b2-0.09NC-0.42NC0.66I0.26I20platelet-activating factor acetylhydrolase, isoform 1b, subunit 299045_atEno20.36I0.34I-0.38NC-0.49NC20enolase 2, gamma neuronal99085_atUsp30.41NC0.22NC0.65I0.4I20ubiquitin specific peptidase 399378_f\_atH2-Q4-0.42NC-0.42NC0.61MI0.53I20histocompatibility 2, Q region locus 499451_atFam102a0.36I0.16NC0.62I0.11NC20family with sequence similarity 102, member A99465_atMecp20.69I0.59I0.08NC-0.04NC20methyl CpG binding protein 299504_atSt8sia30.38I0.2MI-0.22NC-0.3NC20ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 399537_atRuvbl10.03NC-0.28NC0.48I0.1I20RuvB-like protein 199575_atUbqln10.52NC-0.16NC0.6I0.13I20ubiquilin 199597_atGnai20.45I0.23MI-0.11NC-0.34NC20guanine nucleotide binding protein (G protein), alpha inhibiting 299666_atCs0.39I0.14I0.06NC-0.21NC20citrate synthase99893_atFgf130.07NC-0.57NC0.87I0.05I20fibroblast growth factor 13[^8]Table 8Gene expression matrix after 30 days rTMS on cerebrum.Table 8**TC IDGSL1CL2CL3CL4C\*\#Description**102362_i\_atJunb-2.26D-1.89D-1.91D-1.6D04jun B proto-oncogene102371_atNr4a1-1.99D-1.81D-1.8D-1.72D04nuclear receptor subfamily 4, group A, member 1102661_atEgr2-1.29D-1.33D-1.7D-1.69D04early growth response 2102870_atDynlt1a-0.68D-1.04D-0.62D-0.91D04dynein light chain Tctex-type 1A104598_atDusp1-1.41D-1.38D-1.51D-1.49D04dual specificity phosphatase 1160172_atMeg3-1.61D-1.73D-0.68D-0.89D04maternally expressed 3160173_atMeg3-0.91D-1.31D-0.79D-1.15D04maternally expressed 3160901_atFos-2.14D-2.01D-2.08D-1.95D04FBJ osteosarcoma oncogene160970_atOdf2-0.95D-1.24D-1.31D-1.54D04outer dense fiber of sperm tails 2161666_f\_atGadd45b-0.98D-0.99D-1.63D-1.51D04growth arrest and DNA-damage-inducible 45 beta96302_atSrsf7-0.83D-0.73D-0.82D-0.74MD04serine/arginine-rich splicing factor 797752_atSnhg11-1.12D-0.63D-1.24D-0.71D04small nucleolar RNA host gene 1197890_atSgk1-0.8D-1.04D-1.3D-1.59D04serum/glucocorticoid regulated kinase 199109_atIer2-0.92D-1.48D-0.87D-1.29D04immediate early response 2101058_atAmy1-1.11D-0.83D-1.08MD-0.81NC03amylase 1, salivary101583_atBtg2-0.58D-1.06D-0.6NC-1.04D03B cell translocation gene 2, anti-proliferative104410_atMidn-0.72D-0.23NC-1.07D-0.77MD03midnolin104639_i\_atTaf1d-1.01D-0.74D-0.55D-0.63NC03TATA box binding protein (Tbp)-associated factor,RNA polymerase I, D160487_atMyl4-0.35MD-0.38NC-1.02D-0.96D03myosin, light polypeptide 492424_atZfp692-0.86D-0.94D-0.42NC-0.9D03zinc finger protein 69292542_atRsrp1-1.25D-0.75D-0.96D-0.52NC03arginine/serine rich protein 193411_atSema7a-0.51D-0.1NC-1.37D-0.75D03sema domain, immunoglobulin domain (Ig), and GPI membraneanchor, (semaphorin) 7A93619_atPer1-0.9D-0.3NC-1.01D-0.8D03period circadian clock 198579_atEgr1-0.68D-0.57NC-1.42D-1.04D03early growth response 199347_f\_atEml5-0.92D-1.48D-0.97NC-1.44D03echinoderm microtubule associated protein like 5100002_atItih30.54I0.22NC-0.65D-0.82D12inter-alpha trypsin inhibitor, heavy chain 3100592_atGhitm-0.56D-1.06D0.52I-0.01NC12growth hormone inducible transmembrane protein100599_atAtf4-0.82D-0.58D-0.27NC-0.01MI12activating transcription factor 4162457_f\_atHba-a10.7I-1.46D-0.12NC-2.33D12hemoglobin alpha, adult chain 1; hemoglobin alpha, adult chain 293722_atEnsa-0.46MD-0.83D0.38I-0.03NC12endosulfine alpha93909_f\_atNoct-0.61D-0.84D0.35I0.08NC12nocturnin94781_atHba-a10.35I-1.71D-0.38NC-2.42D12hemoglobin alpha, adult chain 197263_s\_atCsnk1d-0.65D-1.23D0.13I-0.4NC12casein kinase 1, delta99009_atNnt0.77I-0.6D-0.1NC-1.56D12nicotinamide nucleotide transhydrogenase99095_atMax-0.62D0.36NC-0.98D0.01I12Max protein100050_atId1-0.75D-0.55NC-0.64D-0.49NC02inhibitor of DNA binding 1100064_f\_atGja10.23NC-0.09NC-0.62D-0.7D02gap junction protein, alpha 1100348_atGm40022-0.82D-0.93MD-1.22NC-1.12NC02predicted gene, 40022100482_atZfp598-0.42D-0.81D-0.33NC-0.64NC02zinc finger protein 598100536_atMobp-0.11NC-0.22NC-0.72D-0.66D02myelin-associated oligodendrocytic basic protein100611_atLyz20.32NC-1.04D0.06NC-1.05D02lysozyme 2101482_atPpp1cc0.08NC-0.04NC-0.59D-0.77D02protein phosphatase 1, catalytic subunit, gamma isoform101580_atCox7b-0.62D-0.43NC-0.71D-0.43NC02cytochrome c oxidase subunit VIIb101596_atC78859-0.96MD-0.8MD-0.66NC-0.91NC02expressed sequence C78859101740_atAdra1a-0.04NC-2.3D-1.47NC-4.05D02adrenergic receptor, alpha 1a[^9]Table 9Gene expression matrix after 30 days rTMS on cerebrum.Table 9**TC IDGSL1CL2CL3CL4C\*\#Description**101869_s\_atHbb-b10.03NC-1.76D-0.05NC-1.94D02hemoglobin, beta adult major chain; hemoglobin, beta adult minorchain; hemoglobin, beta adult s chain; hemoglobin, beta adult t chain101936_atClk4-0.63D-0.73D-0.4NC-0.3NC02CDC like kinase 4101962_atDdx17-0.73D-0.35NC-0.58D-0.19NC02DEAD (Asp-Glu-Ala-Asp) box polypeptide 17102255_atOsmr0.04NC-1.08MD-3.48NC-3.02MD02oncostatin M receptor102431_atMapt-0.01NC-0.04NC-0.61D-0.6D02microtubule-associated protein tau102574_atFgf112.96NC-1.26D3.35NC-0.77D02fibroblast growth factor 11102779_atGadd45b-1.04D-1.15D-0.64NC-0.62NC02growth arrest and DNA-damage-inducible 45 beta102781_atCcnl2-0.78D-0.93D-0.72NC-0.79NC02cyclin L2103253_atLin7b-0.46D-0.39NC-0.64D-0.56NC02lin-7 homolog B (C. elegans)103427_atFbxl3-0.67D-0.63D-0.2NC-0.39NC02F-box and leucine-rich repeat protein 3103448_atS100a82.13NC-2.11D1.42NC-2.74D02S100 calcium binding protein A8 (calgranulin A)103460_atDdit4-0.34NC-0.5NC-1.1D-1.48D02DNA-damage-inducible transcript 4103534_atHbb-b20.17NC-1.63D-0.09NC-2.34D02hemoglobin, beta adult minor chain103811_atInvs-0.58NC-1.39D-1.34NC-2D02inversin103863_atSft2d1-0.41D-0.66D-0.18NC-0.29NC02SFT2 domain containing 1103990_atFosb0.08NC-1.24D-0.3NC-1.35D02FBJ osteosarcoma oncogene B104155_f\_atAtf3-1.59D-2.13D-0.47NC-1.05NC02activating transcription factor 3104578_f\_atActn10.08NC-0.05NC-0.69D-0.86D02actinin, alpha 1104640_f\_atTaf1d-0.02NC-0.47NC-0.68D-0.97D02TATA box binding protein (Tbp)-associated factor,RNA polymerase I, D104701_atBhlhe40-0.38NC-0.42NC-0.87D-0.9D02basic helix-loop-helix family, member e40160140_atTbce-1.09D-0.66NC-0.92D-0.82NC02tubulin-specific chaperone E160182_atSrsf6-0.6D-0.7D-0.45NC-0.56NC02serine/arginine-rich splicing factor 6160316_atAI503316-0.89D-1.11D-0.01NC-0.74NC02expressed sequence AI503316; heterogeneous nuclearribonucleoprotein U160407_atActr1a-1.42D-2.18D-0.11NC-0.68NC02ARP1 actin-related protein 1 A, centractin alpha160547_s\_atTxnip-0.6NC-1.07D-0.7NC-1.28D02thioredoxin interacting protein160564_atLcn2-0.8NC-3.16D-0.92NC-3.84D02lipocalin 2160791_atLuc7l3-0.9D-0.14NC-1.26D-0.37NC02LUC7-like 3 (S. cerevisiae)160894_atCebpd-0.15NC-1.06D-0.34NC-1.37D02CCAAT/enhancer binding protein (C/EBP), delta161462_r\_at6820431F20Rik-1.44NC-2.05D-1.53NC-2.36D02cadherin 11 pseudogene; predicted gene, 21811162093_atYars-0.87D-0.94D-0.07NC-0.35NC02tyrosyl-tRNA synthetase162399_f\_atAtxn2-0.14NC-0.23NC-0.94D-1.23D02ataxin 2162424_f\_atDdx17-0.58D-0.11NC-0.86D-0.23NC02DEAD (Asp-Glu-Ala-Asp) box polypeptide 17162459_f\_atCol6a1-0.11NC-0.78NC-3.33D-4.01D02collagen, type VI, alpha 192211_atBod1l-0.56D-0.69D-0.56NC-0.5NC02biorientation of chromosomes in cell division 1-like92233_atPaxbp1-0.62D-0.93D-0.61NC-0.68NC02PAX3 and PAX7 binding protein 192523_atKcnj60.42NC-1.73D1.6NC-1.02MD02potassium inwardly-rectifying channel, subfamily J, member 692636_f\_atGm10177-0.34D-0.09NC-0.52D-0.23NC02predicted gene 10177; predicted gene, 17756; predicted gene 4184;protein transport protein Sec. 61 subunit gamma; protein transportprotein Sec. 61 subunit gamma-like; SEC. 61, gamma subunit92642_atCar2-0.42MD-0.37NC-0.88D-0.72NC02carbonic anhydrase 292665_f\_at3830403N18Rik-3.41D-3.56NC-3.93D-4.21NC02RIKEN cDNA 3830403N18 gene; X-linked lymphocyte-regulated92751_i\_atWnt10b0.49NC-1.75D-2.13NC-4.2D02wingless-type MMTV integration site family, member 10B92768_s\_atAlas2-0.01NC-1.89D-0.66NC-2.71D02aminolevulinic acid synthase 2, erythroid[^10]Table 10Gene expression matrix after 30 days rTMS on cerebrum.Table 10**TC IDGSL1CL2CL3CL4C\*\#Description**92777_atCyr61-1.09NC-1.87D-1.21NC-2.36D02cysteine rich protein 6192787_atAnkrd10-0.66D-1D-0.31NC-0.69NC02ankyrin repeat domain 1092802_s\_atPlp1-0.61D-0.99D0.03NC-0.42NC02proteolipid protein (myelin) 192945_atGria2-0.45NC-0.06NC-0.96D-0.82D02glutamate receptor, ionotropic, AMPA2 (alpha 2)93009_atGstm2-2D-4.19D-0.85NC-2.44NC02glutathione S-transferase, mu 293126_atCkb-0.01NC-0.12NC-0.53D-0.56D02creatine kinase, brain93274_atClk1-1.11D-1.04D-0.6NC-0.46NC02CDC-like kinase 193285_atDusp6-0.48NC-0.52NC-0.58D-0.83D02dual specificity phosphatase 693353_atLum-0.93D-0.76D0.22NC0.25NC02lumican93390_g\_atProm10.11NC0.05NC-1.44D-1.09D02prominin 193478_atDnajc21-0.14NC-0.07NC-1.02MD-1.39D02DnaJ (Hsp40) homolog, subfamily C, member 2193486_atSlc27a10.53NC-0.65D-0.4NC-1.46D02solute carrier family 27 (fatty acid transporter), member 193615_atPbx30.26NC0.07NC-0.63D-0.94D02pre B cell leukemia homeobox 393666_atLmo2-0.51D-0.72D0.08NC-0.23NC02LIM domain only 293773_f\_atZranb2-0.71D-0.4NC-0.61D-0.41NC02zinc finger, RAN-binding domain containing 293985_atTiparp-1.11D-0.46NC-0.74D-0.79NC02TCDD-inducible poly(ADP-ribose) polymerase94155_atRgs4-0.56MD-0.96D0.49NC-0.31NC02regulator of G-protein signaling 494192_atGdap10-0.41NC-1.15D-0.66NC-1.24D02ganglioside-induced differentiation-associated-protein 1094349_atKhdc1b-2.59NC-4.38D0.41NC-1.57D02KH domain containing 1B94379_atKif1b-1.4NC-1.71D-1.62NC-2.65D02kinesin family member 1B94395_atFubp1-0.48NC-0.78D-0.99D-1.05NC02far upstream element (FUSE) binding protein 194460_atStk38-0.43D-0.79D-0.04NC-0.37NC02serine/threonine kinase 3894516_f\_atPenk0.16NC0.02NC-0.78D-0.89D02preproenkephalin94689_atGm39971-0.03NC-0.48NC-1.5D-2D02predicted gene, 3997195001_atAkap8-0.88D-1MD-0.62NC-0.84NC02A kinase (PRKA) anchor protein 895081_atExosc8-1.38D-1.39D-0.8NC-0.95NC02exosome component 895134_atMid1ip1-0.92D-0.8D-0.3NC-0.2NC02Mid1 interacting protein 1 (gastrulation specific G12-like(zebrafish))95339_r\_atMmp12-2.02MD-4.34D-1.71NC-4.09NC02matrix metallopeptidase 1295418_atRasl11b0.02NC-0.09NC-0.76D-0.85D02RAS-like, family 11, member B95674_r\_atBasp1-0.37D-0.21NC-0.51D-0.3NC02brain abundant, membrane attached signal protein 195694_atTop1-0.2NC-0.4NC-0.56D-0.63D02topoisomerase (DNA) I96464_atPlxnb2-0.41NC-1.64D0.19NC-0.78MD02plexin B296672_atHopx-0.45D-0.64D-0.29NC-0.52NC02HOP homeobox96785_atKank3-0.55D-0.33NC-1.08D-0.92NC02KN motif and ankyrin repeat domains 396912_s\_atCtla2a-0.8D-1.02D-0.38NC-0.77NC02cytotoxic T lymphocyte-associated protein 2 alpha; cytotoxicT lymphocyte-associated protein 2 beta                          96961_atPcgf2-0.35NC-1.18D-0.08NC-0.74D02polycomb group ring finger 297142_atDXErtd242e-1.93D-2.25D-2.93NC-3.23NC02DNA segment, Chr X, ERATO Doi 242, expressed97358_atAdgrl10.02NC0.08NC-0.66D-0.5MD02adhesion G protein-coupled receptor L197759_atKcnma1-0.15NC-0.06NC-0.87D-0.65D02potassium large conductance calcium-activated channel,subfamily M, alpha member 198474_r\_atTnfaip6-1.14D-0.3NC-1.1MD0.04NC02tumor necrosis factor alpha induced protein 698475_atMatn2-0.17NC-0.29NC-0.76D-1.16D02matrilin 299089_atMal-0.28NC-0.61NC-0.92D-1.12D02myelin and lymphocyte protein, T cell differentiation protein99622_atKlf4-0.81NC-0.52NC-2.7D-2.56D02Kruppel-like factor 4 (gut)99830_atKalrn-0.16NC0.04NC-0.89D-0.69D02kalirin, RhoGEF kinase[^11]

2. Experimental design, materials and methods {#s0010}
=============================================

We carried out a comprehensive analysis of altered gene expression in cerebrum following chronic rTMS using a high-density oligonucleotide array (GeneChip; Affymetrix, Santa Clara, CA, USA. MG_U74Av2 probe array), as described elsewhere [@bib2]. Using the Affymetrix algorithm [@bib3] and multiple analysis comparison software for assessing gene expression differences, mRNAs that increased or decreased in the mouse brain following chronic rTMS relative to levels in the control mouse brain were identified. Pathway analysis was used to identify the significant pathway of the differential genes according to KEGG. And also, Gene Ontology (GO) analysis was applied to analyze the main function of the differentially expressed genes according to the gene ontology, which is the key functional classification of NCBI that can organize genes into hierarchical categories and uncover the gene regulatory network based on biological process and molecular function [@bib4].

Using these data, we indicated that rTMS modulates glutamate, GABA and glycine transporters and regulates ER stress-related genes [@bib1].
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[^1]: Present address: Kochi Medical School, Kochi University, Kochi, Japan.

[^2]: Gnb1, Gnai2, Dlg4 and Mapk1 are glutamatergic genes. Fyn, Camk2a and Mapk1 are cholinergic genes. Kif5a is Dopaminergic gene. Mice cerebrum stimulated by rTMS for 30days were denoted as M1 and M2, sham control were denoted as C1 and C2. N=2. All expression ratios were converted into the log~2~(expression ratio) values. L1: Signal Log Ratio (M1/C1), L2: Signal Log Ratio (M2/C1), L3: Signal Log Ratio (M1/C2), L4: Signal Log Ratio (M1/C2). C1, C2 were used as a control and M1, M2 were normalized with respect to C1 and C2 to obtain expression ratios. Expression Console (EC) Ver.1.4 and Transcriptome Analysis Console (TAC) Ver.3. were used for Comparison Analysis as manufacture procedure. C means data analysis output for a Comparison Analysis illustrating Change p-values with the associated Increase (I) or Decrease (D) call. Increase calls have Change p-values closer to zero and Decrease calls have Change p-values closer to one. Finally, the Change algorithm assesses probe pair saturation, calculates a Change p-values, and assigns an (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), or (D) call for C. Gene with more than 2 significant difference calls was chosen. Abbreviations; TC ID: Transcript Cluster ID, GS: Gene Symbol, \*: Total number of increase, \#: Total number of decrease. TC ID is available for Pathway analysis.

[^3]: Actb, Itpr2 and Rho are oxytocin signaling pathway genes. Cyfip1and Itgb4 are actin cytoskeleton regulation genes. Pdpk1 and Pdcd4 are genes of proteoglycans in cancer. Pla2g7 amd Pld4 are ether lipid metabolism genes. Mice cerebrum stimulated by rTMS for 30days were denoted as M1 and M2, sham control were denoted as C1 and C2. N=2. All expression ratios were converted into the log~2~(expression ratio) values. L1: Signal Log Ratio (M1/C1), L2: Signal Log Ratio (M2/C1), L3: Signal Log Ratio (M1/C2), L4: Signal Log Ratio (M1/C2). C1, C2 were used as a control and M1, M2 were normalized with respect to C1 and C2 to obtain expression ratios. Expression Console (EC) Ver.1.4 and Transcriptome Analysis Console (TAC) Ver.3. were used for Comparison Analysis as manufacture procedure. C means data analysis output for a Comparison Analysis illustrating Change p-values with the associated Increase (I) or Decrease (D) call. Increase calls have Change p-values closer to zero and Decrease calls have Change p-values closer to one. Finally, the Change algorithm assesses probe pair saturation, calculates a Change p-values, and assigns an (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), or (D) call for C. Gene with more than 2 significant difference calls was chosen. Abbreviations; TC ID: Transcript Cluster ID, GS: Gene Symbol, \*: Total number of increase, \#: Total number of decrease. TC ID is available for Pathway analysis.

[^4]: Ache is Cholinergic gene. Grik5 and Slc1a1 are Glutamatergic gene. Mice cerebrum stimulated by rTMS for 30days were denoted as M1 and M2, sham control were denoted as C1 and C2. N=2. All expression ratios were converted into the log~2~(expression ratio) values. L1: Signal Log Ratio (M1/C1), L2: Signal Log Ratio (M2/C1), L3: Signal Log Ratio (M1/C2), L4: Signal Log Ratio (M1/C2). C1, C2 were used as a control and M1, M2 were normalized with respect to C1 and C2 to obtain expression ratios. Expression Console (EC) Ver.1.4 and Transcriptome Analysis Console (TAC) Ver.3. were used for Comparison Analysis as manufacture procedure. C means data analysis output for a Comparison Analysis illustrating Change p-values with the associated Increase (I) or Decrease (D) call. Increase calls have Change p-values closer to zero and Decrease calls have Change p-values closer to one. Finally, the Change algorithm assesses probe pair saturation, calculates a Change p-values, and assigns an (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), or (D) call for C. Gene with more than 2 significant difference calls was chosen. Abbreviations; TC ID: Transcript Cluster ID, GS: Gene Symbol, \*: Total number of increase, \#: Total number of decrease. TC ID is available for Pathway analysis.

[^5]: Kcnab2 and Pacsin1 are Synaptosome genes. Rapgef4, Arhgap5 and Ctnna2 are Leukocyte transendothelial migration genes. Mice cerebrum stimulated by rTMS for 30days were denoted as M1 and M2, sham control were denoted as C1 and C2. N=2. All expression ratios were converted into the log~2~(expression ratio) values. L1: Signal Log Ratio (M1/C1), L2: Signal Log Ratio (M2/C1), L3: Signal Log Ratio (M1/C2), L4: Signal Log Ratio (M1/C2). C1, C2 were used as a control and M1, M2 were normalized with respect to C1 and C2 to obtain expression ratios. Expression Console (EC) Ver.1.4 and Transcriptome Analysis Console (TAC) Ver.3. were used for Comparison Analysis as manufacture procedure. C means data analysis output for a Comparison Analysis illustrating Change p-values with the associated Increase (I) or Decrease (D) call. Increase calls have Change p-values closer to zero and Decrease calls have Change p-values closer to one. Finally, the Change algorithm assesses probe pair saturation, calculates a Change p-values, and assigns an (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), or (D) call for C. Gene with more than 2 significant difference calls was chosen. Abbreviations; TC ID: Transcript Cluster ID, GS: Gene Symbol, \*: Total number of increase, \#: Total number of decrease. TC ID is available for Pathway analysis.

[^6]: Rad23b, Sec. 61b, Vimp, Rpn2 and Ssr3 are genes of protein processing in endoplasmic reticulum. Atp1b2 and Camk2a are cAMP signaling pathway genes. Mice cerebrum stimulated by rTMS for 30days were denoted as M1 and M2, sham control were denoted as C1 and C2. N=2. All expression ratios were converted into the log~2~(expression ratio) values. L1: Signal Log Ratio (M1/C1), L2: Signal Log Ratio (M2/C1), L3: Signal Log Ratio (M1/C2), L4: Signal Log Ratio (M1/C2). C1, C2 were used as a control and M1, M2 were normalized with respect to C1 and C2 to obtain expression ratios. Expression Console (EC) Ver.1.4 and Transcriptome Analysis Console (TAC) Ver.3. were used for Comparison Analysis as manufacture procedure. C means data analysis output for a Comparison Analysis illustrating Change p-values with the associated Increase (I) or Decrease (D) call. Increase calls have Change p-values closer to zero and Decrease calls have Change p-values closer to one. Finally, the Change algorithm assesses probe pair saturation, calculates a Change p-values, and assigns an (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), or (D) call for C. Gene with more than 2 significant difference calls was chosen. Abbreviations; TC ID: Transcript Cluster ID, GS: Gene Symbol, \*: Total number of increase, \#: Total number of decrease. TC ID is available for Pathway analysis.

[^7]: Arfgef1, Rab31, Rab11b, Capza2, and Chmp2a are genes of endocytosis. Mice cerebrum stimulated by rTMS for 30days were denoted as M1 and M2, sham control were denoted as C1 and C2. N=2. All expression ratios were converted into the log~2~(expression ratio) values. L1: Signal Log Ratio (M1/C1), L2: Signal Log Ratio (M2/C1), L3: Signal Log Ratio (M1/C2), L4: Signal Log Ratio (M1/C2). C1, C2 were used as a control and M1, M2 were normalized with respect to C1 and C2 to obtain expression ratios. Expression Console (EC) Ver.1.4 and Transcriptome Analysis Console (TAC) Ver.3. were used for Comparison Analysis as manufacture procedure. C means data analysis output for a Comparison Analysis illustrating Change p-values with the associated Increase (I) or Decrease (D) call. Increase calls have Change p-values closer to zero and Decrease calls have Change p-values closer to one. Finally, the Change algorithm assesses probe pair saturation, calculates a Change p-values, and assigns an (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), or (D) call for C. Gene with more than 2 significant difference calls was chosen. Abbreviations; TC ID: Transcript Cluster ID, GS: Gene Symbol, \*: Total number of increase, \#: Total number of decrease. TC ID is available for Pathway analysis.

[^8]: Gnai2, Kif5a and Ppp2r5c are dopaminergic synapse genes. Gnai2, Myh7 and Ppp2r5c are genes of adrenergic signaling in cardiomyocytes. Mice cerebrum stimulated by rTMS for 30days were denoted as M1 and M2, sham control were denoted as C1 and C2. N=2. All expression ratios were converted into the log~2~(expression ratio) values. L1: Signal Log Ratio (M1/C1), L2: Signal Log Ratio (M2/C1), L3: Signal Log Ratio (M1/C2), L4: Signal Log Ratio (M1/C2). C1, C2 were used as a control and M1, M2 were normalized with respect to C1 and C2 to obtain expression ratios. Expression Console (EC) Ver.1.4 and Transcriptome Analysis Console (TAC) Ver.3. were used for Comparison Analysis as manufacture procedure. C means data analysis output for a Comparison Analysis illustrating Change p-values with the associated Increase (I) or Decrease (D) call. Increase calls have Change p-values closer to zero and Decrease calls have Change p-values closer to one. Finally, the Change algorithm assesses probe pair saturation, calculates a Change p-values, and assigns an (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), or (D) call for C. Gene with more than 2 significant difference calls was chosen. Abbreviations; TC ID: Transcript Cluster ID, GS: Gene Symbol, \*: Total number of increase, \#: Total number of decrease. TC ID is available for Pathway analysis.

[^9]: Atf4, Adra1a, Myl4 and Ppp1cc are genes of adrenergic signaling in cardiomyocytes. Fos, Max, Atf4, Dusp1, Gadd45b and Nr4a1 are genes of MAPK signaling pathway. Fos, Atf4 and Ppp1cc are Dopaminergic genes. Csnk1d, Id1 and Ppp1cc are genes of hippo signaling pathway. Csnk1d and Per1 are circadian rhythm genes. Mice cerebrum stimulated by rTMS for 30days were denoted as M1 and M2, sham control were denoted as C1 and C2. N=2. All expression ratios were converted into the log~2~(expression ratio) values. L1: Signal Log Ratio (M1/C1), L2: Signal Log Ratio (M2/C1), L3: Signal Log Ratio (M1/C2), L4: Signal Log Ratio (M1/C2). C1, C2 were used as a control and M1, M2 were normalized with respect to C1 and C2 to obtain expression ratios. Expression Console (EC) Ver.1.4 and Transcriptome Analysis Console (TAC) Ver.3. were used for Comparison Analysis as manufacture procedure. C means data analysis output for a Comparison Analysis illustrating Change p-values with the associated Increase (I) or Decrease (D) call. Increase calls have Change p-values closer to zero and Decrease calls have Change p-values closer to one. Finally, the Change algorithm assesses probe pair saturation, calculates a Change p-values, and assigns an (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), or (D) call for C. Gene with more than 2 significant difference calls was chosen. Abbreviations; TC ID: Transcript Cluster ID, GS: Gene Symbol, \*: Total number of increase, \#: Total number of decrease. TC ID is available for Pathway analysis.

[^10]: Ddit4, Col6a1, Fgf11 and Osmr genes of PI3K-AKT signaling pathway. Fbxl3 and Bhlhe40 are circadian rhythm genes. Mice cerebrum stimulated by rTMS for 30days were denoted as M1 and M2, sham control were denoted as C1 and C2. N=2. All expression ratios were converted into the log~2~(expression ratio) values. L1: Signal Log Ratio (M1/C1), L2: Signal Log Ratio (M2/C1), L3: Signal Log Ratio (M1/C2), L4: Signal Log Ratio (M1/C2). C1, C2 were used as a control and M1, M2 were normalized with respect to C1 and C2 to obtain expression ratios. Expression Console (EC) Ver.1.4 and Transcriptome Analysis Console (TAC) Ver.3. were used for Comparison Analysis as manufacture procedure. C means data analysis output for a Comparison Analysis illustrating Change p-values with the associated Increase (I) or Decrease (D) call. Increase calls have Change p-values closer to zero and Decrease calls have Change p-values closer to one. Finally, the Change algorithm assesses probe pair saturation, calculates a Change p-values, and assigns an (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), or (D) call for C. Gene with more than 2 significant difference calls was chosen. Abbreviations; TC ID: Transcript Cluster ID, GS: Gene Symbol, \*: Total number of increase, \#: Total number of decrease. TC ID is available for Pathway analysis.

[^11]: Lmo2, Pbx3 and Prom1 are genes of transcriptional misregulation in cancer. Mice cerebrum stimulated by rTMS for 30days were denoted as M1 and M2, sham control were denoted as C1 and C2. N=2. All expression ratios were converted into the log~2~(expression ratio) values. L1: Signal Log Ratio (M1/C1), L2: Signal Log Ratio (M2/C1), L3: Signal Log Ratio (M1/C2), L4: Signal Log Ratio (M1/C2). C1, C2 were used as a control and M1, M2 were normalized with respect to C1 and C2 to obtain expression ratios. Expression Console (EC) Ver.1.4 and Transcriptome Analysis Console (TAC) Ver.3. were used for Comparison Analysis as manufacture procedure. C means data analysis output for a Comparison Analysis illustrating Change p-values with the associated Increase (I) or Decrease (D) call. Increase calls have Change p-values closer to zero and Decrease calls have Change p-values closer to one. Finally, the Change algorithm assesses probe pair saturation, calculates a Change p-values, and assigns an (I), Marginal Increase (MI), No Change (NC), Marginal Decrease (MD), or (D) call for C. Gene with more than 2 significant difference calls was chosen. Abbreviations; TC ID: Transcript Cluster ID, GS: Gene Symbol, \*: Total number of increase, \#: Total number of decrease. TC ID is available for Pathway analysis.
